Question 1

What does peer-reviewed research say about these claims?

Accepted Answer

Bro translation: Mainstream medical consensus does not support the claim that 'lingering mycotoxins' cause chronic illness after mold remediation, nor does it validate the use of peptides like BPC-157 or KPV for treating Mold Illness or MCAS; these are experimental therapies with no FDA approval or robust clinical evidence for these conditions. The assertion that 'cutting-edge lab testing' can reliably find 'root causes' of complex systemic illness is also unsupported by standard-of-care guidelines, which often rely on established diagnostic criteria rather than unvalidated functional panels.

Question 2

Are Jaban M Moore's credentials legitimate?

Accepted Answer

Jaban Moore presents as a chiropractor, a real state-regulated credential with a narrower musculoskeletal and nervous-system scope. The site nevertheless markets broad disease-cause assessment and systemic detoxification concepts, creating credential inflation through specialty overreach. Stated credentials: none detected. Likely credentials: Chiropractor (DC), DC. Credential inflation detected, a white coat is not the same as an MD/DO license.

Question 3

Is Dr Jaban M Moore a real medical doctor?

Accepted Answer

Jaban M Moore is not identified as an MD/DO physician in reviewed credentials or public registry data. Likely credential: Chiropractor (DC).

Question 4

Does Jaban M Moore use False Authority?

Accepted Answer

Uses a trademarked, unregulated title to imply a level of medical authority and expertise that is not recognized by state medical boards, conflating a niche philosophy with board-certified competence. Likely motive: To bypass skepticism about non-MD/DO credentials by creating a proprietary, authoritative brand identity.

Question 5

Does Jaban M Moore use Fear Mongering?

Accepted Answer

Suggests that standard remediation is insufficient and that 'hidden' exposures are the inevitable cause of continued sickness, creating anxiety that only the influencer's specific testing can resolve. Likely motive: To drive patients to purchase expensive, non-standard lab testing panels.

Question 6

Does Jaban M Moore use Sales Funnel Motive?

Accepted Answer

Directly pivots from educational content about complex diseases to a paid consultation link, framing the consultation as the only way to 'uncover the root cause' mentioned in the video. Likely motive: To monetize the anxiety generated by the video content through high-ticket coaching/consulting fees.

Question 7

Is the claim "Dr. Jill will search for underlying triggers that are contributing to your illness thro…" supported by medical literature?

Accepted Answer

There is substantial high-quality evidence that personalized or precision medicine can improve outcomes in specific conditions when laboratory or biomarker testing is rigorously validated and integrated into guideline-based care. Systematic reviews and meta-analyses in oncology show that biomarker-guided, personalized targeted therapies are associated with higher response rates, longer progression-free survival, and longer overall survival compared with non-personalized approaches, supporting the general concept that tailoring interventions to individual molecular profiles can be beneficial in cancer. Multiple randomized and observational studies summarized in systematic reviews indicate that biomarker-guided therapy using validated markers (e.g., pharmacogenomic-guided antidepressant therapy, targeted oncologic treatments, susceptibility-guided therapy for Helicobacter pylori, and selected biomarker-guided heart failure strategies) can outperform standard empiric regimens under certain conditions, supporting the idea that investigation of underlying mechanistic or molecular triggers and individualized interventions can be clinically valuable when based on robust evidence. Major clinical guidelines for common chronic diseases (e.g., hypertension management guidelines) endorse some level of individualized care: they recommend tailoring drug selection and dosing to comorbidities, age, race/ethnicity, and sometimes specific lab findings such as renal function or electrolyte status, reflecting a mainstream acceptance of individualized therapy grounded in conventional laboratory testing rather than broad “cutting-edge” panels. Nutrition guidelines for specific disease states (e.g., clinical nutrition in inflammatory bowel disease and parenteral nutrition guidelines) similarly recommend using targeted assessments and standard laboratory tests to identify nutritional deficits or disease-related complications and to tailor nutritional interventions to the patient’s clinical state, again supporting a constrained but genuine form of individualized care. Evidence-based transfusion medicine emphasizes laboratory-guided decisions (hemoglobin thresholds, coagulation tests) and individualized risk–benefit assessments, reinforcing the concept that lab data and patient-specific characteristics are central to tailoring interventions, although this relies on well-established tests rather than broad advanced panels. GRADE methodology papers emphasize rating evidence quality and avoiding overinterpretation of imprecise data, indirectly supporting that any use of lab-based personalization should be grounded in high-quality, precise evidence rather than speculative or unvalidated testing. The influencer’s claim is broad and non-specific, implying that “cutting-edge lab testing” to search for underlying triggers of illness and then tailoring interventions to each individual is generally effective. High-quality evidence and major guidelines do not support the routine use of expansive, non-validated advanced laboratory panels to search for vague “underlying triggers” of chronic illness, especially as commonly promoted in functional or integrative medicine. Instead, they emphasize the use of a limited set of validated tests targeted to specific conditions. Clinical nutrition guidelines in inflammatory bowel disease, for example, do not recommend indiscriminate advanced testing; they call for focused assessment of nutritional status, disease activity, and standard biomarkers to guide therapy. Similarly, ASPEN-FELANPE and parenteral nutrition guidelines stress careful indication and standard lab monitoring, not extensive exploratory advanced lab panels. Hypertension management guidelines illustrate that mainstream, guideline-directed care is primarily driven by well-established measurements (blood pressure readings, basic labs for kidney function and electrolytes) and clinical risk factors, not by broad, cutting-edge biomarker or multi-omics panels to identify idiosyncratic “triggers.” Evidence on biomarker-guided therapy in heart failure and other chronic diseases shows that while biomarker-based strategies can be promising, the overall quality of evidence is often rated low or very low by GRADE, and routine implementation is not recommended without further high-quality trials, indicating that use of many advanced biomarker-guided strategies is still experimental rather than standard practice. Guidelines for tension-type headache management emphasize clinical diagnosis and the avoidance of unnecessary testing, reserving investigations for specific red flags, which contradicts the notion that broad advanced lab testing is routinely needed to search for triggers in common conditions. Transfusion therapy guidance likewise promotes evidence-based thresholds and indications rather than extensive exploratory lab work to find underlying “triggers” of anemia beyond established diagnostics. Overall, no major guideline among the index papers endorses the general practice of an individual clinician routinely ordering wide-ranging, cutting-edge laboratory panels across diseases primarily to search for unspecified triggers, nor do they claim that such an approach is broadly proven to improve outcomes. The evidence base supports selective, disease-specific personalization where markers are validated, not Literature verdict: mixed.

Question 8

Is the claim "Peptides such as BPC-157, KPV, thymosin alpha-1, mitochondrial peptides, and low-dose G…" supported by medical literature?

Accepted Answer

The claim has a limited evidence base only for a subset of the substances and only in narrow contexts. A recent systematic review found BPC-157 shows promise for musculoskeletal injury recovery, but the evidence was almost entirely preclinical: 35 of 36 included studies were preclinical and only 1 was clinical, with no human safety data . Reviews of GLP-1 receptor agonists report anti-inflammatory effects and a meta-analysis found reductions in inflammatory markers in type 2 diabetes, which supports the general idea that GLP-1 drugs can reduce inflammation, though not specifically for mold illness, MCAS, or chronic fatigue . Chronic fatigue syndrome literature does show an inflammatory signal in some patients, with elevated TNF, IL-2, IL-4, TGF-β, and CRP in a meta-analysis, which provides a plausible mechanistic rationale for anti-inflammatory approaches but not proof for these peptides . The claim is not supported by high-quality clinical evidence for mold illness, MCAS, or chronic fatigue. The BPC-157 systematic review explicitly found no clinical safety data and only one clinical study, so use for recovery in these conditions remains unproven . For TB-500/thymosin beta-4-related compounds, the literature summarized in the indexed review says efficacy in sports injuries is unproven and there is a critical gap between preclinical data and human evidence; by extension, this does not establish use for mold illness, MCAS, or chronic fatigue . The indexed materials provided do not supply RCTs, meta-analyses, or major guidelines supporting KPV, thymosin alpha-1, mitochondrial peptides, or low-dose GLP-1 specifically for mold illness or MCAS. The broader literature on GLP-1 anti-inflammatory effects is largely in diabetes/obesity populations and does not validate the influencer’s specific clinical use claim . Mainstream medicine does not recognize BPC-157, KPV, thymosin alpha-1, mitochondrial peptides, or low-dose GLP-1 as established treatments for mold illness, MCAS, or chronic fatigue. The evidence base is best described as preliminary for BPC-157 in musculoskeletal recovery and mechanistic or disease-adjacent for GLP-1 receptor agonists, while human evidence for the other peptides and for these specific indications is absent or very weak . Literature verdict: unsupported.

Advertised	Verdict
Peptides such as BPC-157, KPV, thymosin alpha-1, mitochondrial peptides, and low-dose GLP-1 therapies are being used to support recovery in patients with mold illness, MCAS, chronic fatigue, and inflammation. Rule: RSMo § 331.010.1 Using or providing peptide and GLP-1 therapies is drug or medicine treatment and is expressly excluded from Missouri chiropractic practice.	Outside scope
Diagnosing and treating systemic autoimmune/neurological conditions (MCAS, Mold Illness) with peptide therapy, which is outside the scope of Naturopathic or Chiropractic licenses. Rule: RSMo § 331.010.1 Diagnosing and treating systemic medical conditions with peptide therapy exceeds the chiropractic authorization limited to malpositioned articulations and structures and also involves excluded medical and drug treatment.	Outside scope
Peptide therapy for Mold/MCAS Rule: RSMo § 331.010.1 Peptide therapy for Mold or MCAS is drug or medicine treatment and is not affirmatively authorized within Missouri's chiropractic scope.	Outside scope
Dr. Jill will search for underlying triggers that are contributing to your illness through cutting-edge lab testing and tailor the intervention to your specific needs as an individual. Rule: RSMo § 331.010.1 Searching for underlying causes of illness through broad laboratory evaluation and tailoring medical interventions is not affirmatively authorized by the chiropractic definition, which limits diagnosis and treatment to malpositioned articulations and structures and related neuromusculoskeletal or musculoskeletal function.	Outside scope
Listed service Functional Medicine Expert Rule: RSMo § 331.010.1 Holding oneself out as a functional-medicine expert implies practice of medicine beyond the affirmative chiropractic authorization, which is confined to the statutory practice of chiropractic.	Outside scope
Using 'cutting-edge lab testing' to find 'root causes' of complex systemic illness, a practice often outside the scope of non-MD/DO licenses which are limited to specific modalities. Rule: RSMo § 331.010.1 Broad laboratory investigation of complex systemic illness and root causes is not affirmatively authorized for Missouri chiropractors under § 331.010 and is outside the statute's structure-focused diagnostic scope.	Outside scope
Cutting-edge lab testing for root cause Rule: RSMo § 331.010.1 Root-cause laboratory testing for systemic illness is not affirmatively permitted by Missouri's chiropractic scope statute and does not fall within diagnosis of malpositioned articulations and structures.	Outside scope

Jaban M Moore alias Dr. Peptide Profit

Score breakdown

Key findings

Claims & evidence

Manipulation

Borrowed authority & guest funnel

Host self-funnel

Commerce & grift map

Labs pitched

How the money flows

Sponsors and advertisers

Credentials & scope

Permitted scope vs advertised

What this license permits

Validated associated properties

Analyzed

Funnel routes (third-party)

Tip the jar

Fight disinformation

Log a new mention

Reply snippets

Recent mentions (this doc)

Know someone who can help?

Who should we nudge?

What gets sent

Whambulance

Public challenge log

File a challenge

Citations